Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in EUR (TTM)1.47bn
- Net income in EUR-186.17m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zealand Pharma A/S | 49.36m | -95.50m | 7.33bn | 288.00 | -- | 5.80 | -- | 148.43 | -11.69 | -11.69 | 6.06 | 132.48 | 0.0603 | 4.88 | 2.30 | 1,454,435.00 | -11.67 | -42.74 | -12.12 | -50.24 | 90.96 | 96.13 | -193.49 | -464.66 | 35.57 | -- | 0.0399 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Qiagen NV | 1.77bn | 66.23m | 8.89bn | 5.90k | 136.59 | 2.84 | 34.53 | 5.03 | 0.2899 | 0.2899 | 7.91 | 13.96 | 0.3252 | 2.01 | 5.57 | 296,242.10 | 1.22 | 5.41 | 1.47 | 6.53 | 63.03 | 64.65 | 3.75 | 16.35 | 1.46 | -- | 0.2916 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Genmab A/S | 2.54bn | 738.00m | 14.09bn | 2.53k | 18.92 | 3.25 | -- | 5.54 | 83.89 | 83.89 | 289.07 | 487.96 | 0.5373 | 13.82 | 3.49 | 8,605,717.00 | 15.59 | 17.43 | 17.13 | 18.59 | 96.83 | -- | 29.01 | 35.87 | 5.02 | -- | 0.0319 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 1.47bn | -186.17m | 28.88bn | 1.15k | -- | 7.44 | -- | 19.62 | -3.17 | -3.17 | 24.99 | 64.94 | 0.4043 | 0.6484 | 3.94 | 1,281,910.00 | -5.11 | -17.65 | -5.70 | -19.79 | 89.41 | -- | -12.65 | -97.72 | 7.88 | -- | 0.0079 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Lonza Group AG | 7.11bn | 608.25m | 40.25bn | 17.83k | 66.15 | 3.92 | 33.32 | 5.66 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 20 May 2024 | 2.95m | 4.97% |
Schroder Investment Management Ltd.as of 31 May 2024 | 2.15m | 3.62% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 2.08m | 3.50% |
Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 3.06% |
Norges Bank Investment Managementas of 06 Aug 2024 | 1.69m | 2.85% |
BlackRock Fund Advisorsas of 31 Jul 2024 | 1.16m | 1.96% |
Federated Global Investment Management Corp.as of 30 Jun 2024 | 869.64k | 1.46% |
Bellevue Asset Management AGas of 31 Mar 2024 | 770.00k | 1.30% |
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 513.16k | 0.86% |
Polar Capital LLPas of 28 Jun 2024 | 427.82k | 0.72% |